Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
Abstract Background Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept. The present study evaluates effectiveness of intravitreal inje...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2022-06-01
|
| coleção: | BMC Ophthalmology |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12886-022-02503-x |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|